Members of our founding team possess decades of hand-on experience in research and development of protein and gene therapeutics including track records of project management in both academic and industrial settings. Together these dovetailed expertise and professional experiences form the company’s core competence and forward vision. ABB has also retained John Ripple as our Senior Business Advisor, as well as Peter Rosenblum of Foley Hoag as our Corporate Attorney.
An accomplished protein biochemist specialized in engineering of immunological molecules. Prior to co-founding AB Biosciences, Dr. Hsu was heading the protein engineering group in Research at Biogen where he worked more than two decades. Dr. Hsu has engineered 150+ protein molecules and has over 35 patents granted.
Dr. Jeng-Shin Lee is the Chief Scientific Officer at AB Biosciences, Inc. With a combination of molecular biology training and medical background, Dr. Lee brings decades of experience in gene transfer technology and early product development in biologics, gene and cell therapy.
Senior Business Advisor
John Ripple is CEO of Exonics Therapeutics. Previously, John served as CEO of Ensemble, Permeon, Virdante, and Syntonix. He founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development and fundraising. John received a B.S. in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.
Peter Rosenblum is co-chair of Foley Hoag's Mergers & Acquisitions Group and chair of its Private Equity Transactions Group. Peter is actively involved in the firm’s corporate and corporate finance practices and is principal outside counsel to numerous public and private companies in technology, life sciences and other industries. Peter was Foley Hoag’s Co-Managing Partner from 2000 to 2005 and Chairman of its Business Department from 2008 to 2011.